The Protective Role of α2HS-Glycoprotein in Liver Failure from Hepatitis B
Author Information
Author(s): Dai Xia-Hong, Zhang Pan, Xiao Mei-Fang, Zhou Rong-Rong, Zhang Bao-Xin, Hu Guan-Sheng, Huang Ze-Bing, Fan Xue-Gong
Primary Institution: Xiangya Hospital, Central South University
Hypothesis
α2-Heremans-Schmid glycoprotein may reduce secondary hepatic injury by inhibiting excessive inflammation in patients with viral hepatitis and/or liver failure.
Conclusion
The study found that low serum levels of α2-Heremans-Schmid glycoprotein are associated with liver damage and poor prognosis in hepatitis B patients.
Supporting Evidence
- Serum α2-Heremans-Schmid glycoprotein levels were significantly lower in acute-on-chronic liver failure patients compared to chronic hepatitis B patients and healthy controls.
- A negative correlation was found between serum α2-Heremans-Schmid glycoprotein and tumor necrosis factor-α levels.
- The study suggests that α2-Heremans-Schmid glycoprotein may serve as an independent marker of liver damage.
Takeaway
This study shows that a protein called α2-Heremans-Schmid glycoprotein helps protect the liver, and low levels of it can mean more serious liver problems.
Methodology
The study measured serum levels of α2-Heremans-Schmid glycoprotein and tumor necrosis factor-α in 100 hepatitis B patients and analyzed cytokine release from stimulated peripheral blood mononuclear cells.
Potential Biases
Potential biases may arise from the exclusion of patients with co-infections or other liver diseases.
Limitations
The study had a relatively small sample size and did not account for all possible confounding factors.
Participant Demographics
The study included 100 hospitalized patients with chronic hepatitis B and HBV-related acute-on-chronic liver failure, along with 12 healthy controls.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website